Less than one in 10 people eligible to benefit from GLP-1 drugs including Wegovy are able to get them, states the WHO as it issues its first guidance on the therapies.
With in excess of 1,000,000,000 people worldwide now obese, it is advocating for broader and more equitable availability to these injectable treatments.
Per forecasts, more than two billion are projected to be obese by 2030 without intervention.
"Our new guidance affirms that obesity is a lifelong illness that can be treated with comprehensive and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant barriers to widespread access to the injections that can assist patients in reducing significant weight, notes the agency.
Weight-Loss Drug Shortage
Even under the present most favorable case, the manufacturing of these medications could only cover approximately 100 million people – under 10% of the global need, according to the WHO.
The recommendation urges countries and companies to widen access, via measures such as patent sharing.
Exclusive production rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in several nations in 2026.
The Way Obesity Jabs Function
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, curb appetite and increase the sense of being full so people eat less.
Individuals usually see weight reduction in the initial weeks of commencing the once-weekly jabs.
Studies points to users may regain a significant portion within a year of stopping the drug, because their usual appetite come back.
Being overweight or obese elevates your risk for experiencing medical conditions, including type 2 diabetes, heart disease, brain attack, and certain cancers.
Obesity impacts individuals in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, according to the health agency.
